Lv6
2800 积分 2023-09-16 加入
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
1天前
待确认
Immunotherapy of MSI Cancer: Facts and Hopes
5个月前
已完结
Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status
5个月前
已完结
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability
5个月前
已完结
Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study
5个月前
已完结
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
5个月前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
5个月前
已完结
皖公网安备34019202002308
